Form 4: Aclaris Therapeutics Director Exercises Stock Options
SEC Form 4 Filing
Christopher P. Molineaux, a director at Aclaris Therapeutics, Inc., exercised stock options on June 1, 2024, resulting in the acquisition of 4,660 shares of common stock.
Summary
- On June 1, 2024, Christopher P. Molineaux, a director of Aclaris Therapeutics, Inc., exercised restricted stock units.
- This transaction resulted in the acquisition of 4,660 shares of common stock.
- Following the transaction, Molineaux directly owns 53,163 shares of Aclaris Therapeutics, Inc.
- Matthew Rothman, Attorney-in-Fact, signed the form on June 4, 2024.
Sentiment
Score: 5
Explanation: This is a neutral filing related to standard stock option exercises. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to insider transactions and is a standard practice for publicly traded companies. It provides transparency regarding the trading activities of company directors.
Key Dates
| Date | Description |
|---|---|
| 05/30/2024 | Date of execution for Power of Attorney |
| 06/01/2024 | Date of transaction: Exercise of restricted stock units and vesting of shares. |
| 06/04/2024 | Date of filing: Form 4 signed by Attorney-in-Fact. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.